LGVN News and Press, Longeveron Inc. From 06/28/24

2024-06-28 16:24:47 ET More on Longeveron Longeveron announces exercise of warrants for $4.4M gross proceeds Longeveron announces launch of contract development and manufacturing business Read the full article on Seeking Alpha For further details see: Lon...

Longeveron (NASDAQ: LGVN) is a clinical stage regenerative medicine biotechnology company developing cellular therapies for rare, life-threatening and chronic aging-related conditions. Longeveron presented at the Virtual Life Sciences Investor Forum on June 20. The company’s presentation ...

NEW YORK, June 21, 2024 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced the presentations from the Life Science Virtual Investor Forum held June 20 th are now available for online viewing. REGISTER NOW AT : ...

2024-06-19 10:30:54 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Penny stocks are a tripwire for mayhem. They can easily blow up your portfolio. It’s why often the best advice to follow when looking for penny stocks to buy is to don’t. ...

2024-06-18 17:05:37 ET More on Longeveron Longeveron Inc. (LGVN) Q1 2024 Earnings Call Transcript Longeveron announces exercise of warrants for $4.4M gross proceeds Longeveron announces launch of contract development and manufacturing business Seeking Alpha&#...

MIAMI, June 18, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) (“Longeveron” or the “Company”), a clinical stage regenerative medicine biotechnology company developing cellular therapies for rare, life-threatening and chronic aging-related conditions, tod...

NEW YORK, June 18, 2024 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series announced the agenda for the Life Sciences Virtual Investor Forum to be held on June 20 th , 2024. This event is co-sponsored by Zack’s Small Cap Research. ...

2024-06-17 09:45:40 ET Palm Beach, FL – June 17, 2024 – According to a report from Mordor Intelligence the Acute Myeloid Leukemia Market size is estimated at USD 1.83 billion in 2024, and is expected to reach USD 2.97 billion by 2029, growing at a CAGR of 10.15% during the...

2024-06-17 09:07:35 ET More on Longeveron Longeveron announces launch of contract development and manufacturing business Longeveron announces board transitions Seeking Alpha’s Quant Rating on Longeveron Historical earnings data for Longeveron ...

MIAMI, June 17, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, including hypoplastic left heart syndrome (HLHS) and Alzheimer’...